THE 2024 ANNUAL BOHO GALA
Treating Lung Cancer, Supporting Patients
Saturday, May 18, 2024
5:15 pm Lung Cancer Survivor’s Reception
6:00 pm Gala Starts
The Ohio Union
1739 N. High St.
2nd floor Ballroom
Columbus OH, 43210
Email Ashely Clark at Ashley.clark2@osumc.edu with any questions about additional payment options, and for general questions about the event, please contact Katie Hughes at Katherine.hughes@osumc.edu or call (614) 685-4479.
Funds from this event directly benefit lung cancer research at :
The “Breath of Hope Ohio” Gala was initiated by Sandy and Mark Lomeo after Mark was diagnosed with lung cancer in April 2014. They were surprised to discover the lack of funding for lung cancer as compared to many other types of cancer. They decided to raise money by having a dinner gala. They formed a steering committee (created by Annie Cacciato) to advance their cause. Fundraising efforts from the event support “Blue Beautiful Skies” Fund to directly benefit the Thoracic Oncology Department at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) for awareness, research, new treatments, and hopefully a cure. Presently, lung cancer has a dismal survival rate. It kills more people per year than breast, colon, and prostate cancer combined. In fact, lung cancer kills twice as many women as breast cancer. Given the poor survival rates of lung cancer, your help is needed. Please, support “Breath of Hope Ohio” and its mission by either attending the upcoming event or by donating at Make your gift to The Ohio State University (osu.edu).
Thank you to our 2023 sponsors:
Genentech
AstraZeneca
Lilly Oncology
Check out the recap from the 2022 Breath of Hope Celebration:
Funds raised from these events go directly towards lung cancer research.
Here are some recent lung cancer research breakthroughs past events have contributed to:
5-year survival has doubled in the last decade. This is unprecedented.
With CT screening, more people are diagnosed at stage I than ever before, allowing for early intervention and longer survival.
More people with metastatic lung cancer are alive, doing well, and off all therapy 5+ years after diagnosis.
Comprehensive genomic testing is being used to tailor treatment to the genetic makeup of individual tumors with minimally toxic oral therapies. This is producing long-lasting tumor shrinkage in almost everyone.
New immunotherapies that harness the body’s immune system are effectively fighting the cancer better than chemotherapy and with less toxicity.